Our top pick for
Building a portfolio
Atossa Therapeutics, Inc is a biotechnology business based in the US. Atossa Therapeutics shares (ATOS) are listed on the NASDAQ and all prices are listed in US Dollars. Atossa Therapeutics employs 6 staff and has a market cap (total outstanding shares value) of USD$215.3 million.
|52-week range||USD$0.81 - USD$5.08|
|50-day moving average||USD$2.4114|
|200-day moving average||USD$1.9913|
|Wall St. target price||USD$6.38|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.514|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-31.85%|
|Return on equity TTM||-88.42%|
|Market capitalisation||USD$215.3 million|
TTM: trailing 12 months
There are currently 10.0 million Atossa Therapeutics shares held short by investors – that's known as Atossa Therapeutics's "short interest". This figure is 52.3% up from 6.6 million last month.
There are a few different ways that this level of interest in shorting Atossa Therapeutics shares can be evaluated.
Atossa Therapeutics's "short interest ratio" (SIR) is the quantity of Atossa Therapeutics shares currently shorted divided by the average quantity of Atossa Therapeutics shares traded daily (recently around 12.2 million). Atossa Therapeutics's SIR currently stands at 0.82. In other words for every 100,000 Atossa Therapeutics shares traded daily on the market, roughly 820 shares are currently held short.
However Atossa Therapeutics's short interest can also be evaluated against the total number of Atossa Therapeutics shares, or, against the total number of tradable Atossa Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Atossa Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Atossa Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.0831% of the tradable shares (for every 100,000 tradable Atossa Therapeutics shares, roughly 83 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Atossa Therapeutics.
Find out more about how you can short Atossa Therapeutics stock.
We're not expecting Atossa Therapeutics to pay a dividend over the next 12 months.
Atossa Therapeutics's shares were split on a 1:12 basis on 19 April 2018. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Atossa Therapeutics shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Atossa Therapeutics shares which in turn could have impacted Atossa Therapeutics's share price.
Over the last 12 months, Atossa Therapeutics's shares have ranged in value from as little as $0.81 up to $5.08. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Atossa Therapeutics's is 2.2217. This would suggest that Atossa Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Atossa Therapeutics, Inc. , a clinical-stage biopharmaceutical company, discovers and develops medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; AT-H201, a drug candidate to improve lung function in COVID-19 patients; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. Atossa Therapeutics, Inc. has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the potential treatment of breast cancer.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZIONL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.